NCT02155101View on ClinicalTrials.gov

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
HIV/AIDS
Interventions
DRUG

Darunavir

Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.

DRUG

ART with 2 NRTIs plus LPV/r (or ATV/r)

Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.

Trial Locations (1)

5777

Yaounde Central Hospital, Yaoundé

Sponsors

Collaborators (1)

Janssen Pharmaceutica
All Listed Sponsors
collaborator

Janssen Pharmaceutica

INDUSTRY

collaborator

Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS

OTHER_GOV

collaborator

Yaounde Central Hospital

OTHER_GOV

lead

University of Liverpool

OTHER